Aeon biopharma announces clinical update and productive end-of-phase 2 meeting with fda on abp-450 (prabotulinumtoxina) for the preventive treatment of migraine

– fda and aeon align on the design and endpoints for the proposed pivotal phase 3 trials for the preventive treatment of both episodic and chronic migraine –

AEON Ratings Summary

AEON Quant Ranking